Bide Pharmatech Co

Bide Pharmatech Co Gross Margin

The Gross Margin of Bide Pharmatech Co (688073.SS) as of Oct 17, 2026 is 44.54 %. In the previous year, Gross Margin was 41.33 % — a change of 7.75% (higher).

Gross Margin

44.54 %

YoY

7.75%

Last updated:

Gross Margin of Bide Pharmatech Co is 2025 44.54 % . Gross Margin of Bide Pharmatech Co was 2024 41.33 % . It decreases by 7.75% higher compared to the previous year.

For Bide Pharmatech Co, the gross margin of 44.5% is down versus 49.5% a few years ago.

The Bide Pharmatech Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
55.76 CNY
Jan 1, 2020
54.38 CNY
Jan 1, 2021
49.46 CNY
Jan 1, 2022
44.38 CNY
Jan 1, 2023
40.00 CNY
Jan 1, 2024
41.33 CNY
Jan 1, 2025
44.54 CNY
The Bide Pharmatech Co Gross Margin history
YEARGross MarginYoY
44.54 %+7.75%
41.33 %+3.33%
40.00 %-9.87%
44.38 %-10.27%
49.46 %-9.04%
54.38 %-2.49%
55.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bide Pharmatech Co Stock analysis

What does Bide Pharmatech Co do? Bide Pharmatech Co Ltd is a pharmaceutical company headquartered in Shanghai, China, operating within the Health Care sector. The company focuses on the research, development, design, production, and sales of drug molecular building blocks, which are essential components in pharmaceutical manufacturing. Its main products include pharmaceutical molecular building blocks and scientific reagents, utilized in various stages of drug development such as target discovery, compound screening, and synthesis optimization. Bide Pharmatech employs 617 full-time staff and completed its initial public offering (IPO) on October 11, 2022. The company serves markets across the Asia Pacific region, India, Europe, and the United States. Its website is https://www.bidepharmatech.com/. The firm's operations are centered on providing specialized chemical solutions for the pharmaceutical industry, supporting the development of new drugs and therapeutic compounds. Bide Pharmatech does not disclose specific details about its founding year, key executives, or acquisition history. Financial figures beyond the employee count and IPO date are not provided in the available information. The company operates as a publicly traded entity under the ticker symbol 688073.SS and ISIN CNE100005NV3. It maintains a presence in multiple global markets, emphasizing its role in the pharmaceutical supply chain as a supplier of critical molecular components. Bide Pharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bide Pharmatech Co stock

Gross Margin of Bide Pharmatech Co is 44.54 % in 2025.

Gross Margin of Bide Pharmatech Co changed from 41.33 % to 44.54 %, representing a 7.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Bide Pharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Bide Pharmatech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bide Pharmatech Co

All Key Metrics — Bide Pharmatech Co